866-997-4948(US-Canada Toll Free)

Global Biosimilars Partnering Terms and Agreements 2014 to 2019

Published By :

Current Partnering

Published Date : Aug 2019

Category :

Pharmaceutical

No. of Pages : 90 Pages

The Global Biosimilars Partnering Agreements 2014-2019 report provides an understanding and access to the biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in biosimilars partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • biosimilarspartnering contract documents
  • Top biosimilars deals by value

The Global Biosimilars Partnering Terms and Agreements 2014-2019 report provides an understanding and access to the biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter biosimilarspartnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors biosimilarstechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

This report provides details of the latest biosimilars, oligonucletides including aptamers agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all biosimilars partnering deals announced since 2014 including financial terms where available including over 500 links to online deal records of actual biosimilars partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of biosimilars dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biosimilars dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading biosimilars deals since 2014. Deals are listed by headline value, signed by big pharma, most active biosimilars dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in biosimilars dealmaking with a brief summary followed by a comprehensive listing of biosimilars deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of biosimilars partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 lists biosimilars/biobetters deals by technology type.

Chapter 7 provides a comprehensive and detailed review of biosimilars partnering deals signed and announced since Jan 2014. The chapter is organized by specific biosimilars technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by biosimilars partnering company A-Z, deal type definitions and biosimilars partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in biosimilars partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biosimilars technologies and products.

Report scope

Global Biosimilars Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to biosimilars trends and structure of deals entered into by leading companies worldwide.

Global Biosimilars Partnering Terms and Agreements includes:

  • Trends in biosimilars dealmaking in the biopharma industry since 2014
  • Analysis of biosimilars deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life biosimilars deals
  • Access to over 70 biosimilars deals
  • The leading biosimilars deals by value since 2014
  • Most active biosimilars dealmakers since 2014
  • The leading biosimilars partnering resources

 In Global Biosimilars Partnering Terms and Agreements, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. 

Table of Content

Chapter 1 – Introduction

Chapter 2 – Trends in biosimilars dealmaking
2.1. Introduction
2.2. Biosimilars partnering over the years
2.3. Most active biosimilars dealmakers
2.4. Biosimilars partnering by deal type
2.5. Biosimilars partnering by therapy area
2.6. Deal terms for biosimilars partnering
2.6.1 Biosimilars partnering headline values
2.6.2 Biosimilars deal upfront payments
2.6.3 Biosimilars deal milestone payments
2.6.4 Biosimilars royalty rates

Chapter 3 – Leading biosimilars deals
3.1. Introduction
3.2. Top biosimilars deals by value

Chapter 4 – Most active biosimilars dealmakers
4.1. Introduction
4.2. Most active biosimilars dealmakers
4.3. Most active biosimilars partnering company profiles

Chapter 5 – Biosimilars contracts dealmaking directory
5.1. Introduction
5.2. Biosimilars contracts dealmaking directory

Chapter 6 – Biosimilars dealmaking by technology type

Chapter 7 – Partnering resource center
7.1. Online partnering
8.2. Partnering events
8.3. Further reading on dealmaking

Appendices

Appendix 1 – Biosimilars deals by company A-Z

Appendix 2 – Biosimilars deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 – Biosimilars deals by deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Evaluation
Grant
Joint venture
Licensing
Manufacturing 
Marketing
Option
Research
Spin out
Sub-license
Supply
Technology transfer

Appendix 4 – Biosimilars deals by therapy area
Cardiovascular
Central Nervous System
Genetic disorders
Hematology
Immunology
Infectives
Metabolic
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Orphan disease
Pediatrics
Respiratory

Appendix 5 –Deal type definitions
About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

List of Chart

Figure 1: Biosimilars partnering since 2014
Figure 2: Active biosimilars dealmaking activity since 2014
Figure 3: Biosimilars partnering by deal type since 2014
Figure 4: Biosimilars partnering by disease type since 2014
Figure 5: Biosimilars deals with a headline value
Figure 6: Biosimilars deals with an upfront value
Figure 7: Biosimilars deals with a milestone value
Figure 8: Biosimilars deals with a royalty rate value
Figure 9: Top biosimilars deals by value since 2014
Figure 10: Most active biosimilars dealmakers since 2014
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *